Tagged with P

Switzerland Dominik Escher, Managing Partner of Pureos Bioventures explores the firm’s strategic focus on drug development, particularly in biologics and antibody-based therapeutics. With a keen emphasis on the Swiss biotech ecosystem, Escher discusses the firm’s investment approach and its commitment to fostering innovation in Europe and beyond.   Swiss biotech stands…

Switzerland Emanuele Ostuni, CEO of ARTBIO, delves into the company’s innovative approach to radioligand therapies, focusing on its potential to replace chemotherapy and provide more effective treatment options for patients. Ostuni emphasizes the company’s commitment to precision oncology, with a strong team spread across Switzerland, Norway, USA, and the UK.  …

Puerto Rico Long recognized for its strengths in manufacturing and distribution, Puerto Rico is looking to capitalize on its positive attributes and position itself as a centre for innovation. While important tax incentives have provided stimulus for R&D, the US territory is also working on building a strong local ecosystem, developing and…

USA For those concerned that opinion and not science may determine US public health policy under president-elect Trump, the choice of surgeon Martin Makary as head of the FDA may be reassuring. While Makary is known as a healthcare critic, his views appear to be far less extreme than the controversial…

France A roundup of the top stories coming out of France’s pharma industry, including Sanofi’s consumer health unit spinout and EUR 40 million investment in antibody bioproduction; the French govenment’s unprecedented deal with Upsa; the Health Minister’s plans to lower the national social security system’s reimbursement of drugs; Servier’s newfound willingness…

Global Scott D. Ramsey of the Fred Hutchinson Cancer Center discusses the trend driving pharmaceutical companies to reorganize or eliminate their health economics and outcomes research (HEOR) groups. The original version of this article was featured in the September/October edition of ISPOR’s Value & Outcomes Spotlight magazine.   Last spring, I had…

Puerto Rico As president of Puerto Rico’s Colegio de Químicos (CQPR), Dr. José A. Pérez Meléndez is focused on elevating the US territory’s standards of chemistry education and creating a bridge between industry and academia. He remarks on the Colegio’s strategic partnerships and talent retention efforts aimed at solidifying Puerto Rico’s standing…

UAE Baptiste de Clarens lays out how Sanofi is leveraging its innovative vaccine pipeline, including high-dose flu vaccines and RSV monoclonal antibodies, to drive growth in the GCC region. Despite challenges like vaccine scepticism in adult immunisation, the company is focused on strengthening vaccination infrastructure and public health awareness. de Clarens…

Switzerland Marianthi Psaha, President, Head of EMEA for Santen, discusses the company’s journey towards becoming a specialized leader in ophthalmology—highlighting how digital transformation, innovation in myopia treatment, and strategic partnerships are reshaping its impact on eye health across Europe. Psaha delves into the challenges of building awareness of the area’s importance…

Global With the emergence of GLP-1 RA therapies the obesity drug market has taken off and stands to be worth some USD 125.3 billion by 2033. Eli Lilly and Novo Nordisk may lead the charge, but other contenders are looking to get a piece of this lucrative market as the two…

Global Dr Catherine Duggan, CEO of the International Pharmaceutical Federation, lays out how mental health systems must shift from reactive crisis intervention to proactive, patient-centered approaches; why traditional care models need reimagined funding that prioritises community mental health services and incentivises innovation; and the vital role that pharmacists, as accessible healthcare…

Switzerland Dr Isabelle Dahinden, General Manager of CSL Behring Switzerland, introduces the company’s unique history and strategic focus on plasma-derived treatments. Dr. Dahinden also discusses CSL Behring’s strong presence in Switzerland, including their extensive R&D, production capabilities, and partnerships, while touching on the challenges of navigating the Swiss healthcare landscape.  …